Minimizing the risk of posttransplant malignancy

Area of Science:

• Nephrology
• Oncology
• Immunology

Background:

• Cancer is the second leading cause of death in renal transplant recipients with functioning grafts.
• The incidence of cancer is significantly higher (10-20 times) in transplant patients compared to the general population.
• Calcineurin inhibitor immunosuppressive therapy is implicated in increasing neoplasia risk.

Purpose of the Study:

• To investigate the potential preventive role of mammalian target of rapamycin (mTOR) in cancer development among renal transplant patients.
• To explore mTOR's effect on specific malignancies prevalent in this patient group.

Main Methods:

• Review of existing evidence and clinical data.
• Analysis of the impact of immunosuppressive agents on cancer incidence.
• Evaluation of studies on mTOR inhibitors and their association with cancer risk.

Main Results:

• Calcineurin inhibitors are associated with an increased risk of various cancers.
• Emerging evidence suggests a potential preventive effect of mammalian target of rapamycin (mTOR) therapy.
• mTOR may reduce the incidence of skin cancer, Kaposi's sarcoma, and renal cell carcinoma.

Conclusions:

• Mammalian target of rapamycin (mTOR) therapy shows promise in mitigating cancer risk in renal transplant recipients.
• Further research is warranted to confirm the protective role of mTOR in preventing specific cancers post-transplantation.